nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—Colitis—Doxorubicin—liver cancer	0.00114	0.0023	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00113	0.00228	CcSEcCtD
Rasagiline—Hypertonia—Epirubicin—liver cancer	0.00113	0.00227	CcSEcCtD
Rasagiline—Vaginal infection—Doxorubicin—liver cancer	0.00112	0.00226	CcSEcCtD
Rasagiline—Neuropathy—Doxorubicin—liver cancer	0.00112	0.00225	CcSEcCtD
Rasagiline—Dyspnoea—Sorafenib—liver cancer	0.0011	0.00223	CcSEcCtD
Rasagiline—Cramps of lower extremities—Doxorubicin—liver cancer	0.00109	0.0022	CcSEcCtD
Rasagiline—Dyspepsia—Sorafenib—liver cancer	0.00109	0.0022	CcSEcCtD
Rasagiline—Oesophagitis—Doxorubicin—liver cancer	0.00109	0.00219	CcSEcCtD
Rasagiline—Phlebitis—Epirubicin—liver cancer	0.00108	0.00218	CcSEcCtD
Rasagiline—Decreased appetite—Sorafenib—liver cancer	0.00108	0.00217	CcSEcCtD
Rasagiline—Thrombophlebitis—Epirubicin—liver cancer	0.00108	0.00217	CcSEcCtD
Rasagiline—Ecchymosis—Doxorubicin—liver cancer	0.00107	0.00217	CcSEcCtD
Rasagiline—Neoplasm—Doxorubicin—liver cancer	0.00107	0.00217	CcSEcCtD
Rasagiline—Mouth ulceration—Doxorubicin—liver cancer	0.00107	0.00217	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Sorafenib—liver cancer	0.00107	0.00216	CcSEcCtD
Rasagiline—Constipation—Sorafenib—liver cancer	0.00106	0.00214	CcSEcCtD
Rasagiline—Vascular purpura—Epirubicin—liver cancer	0.00104	0.0021	CcSEcCtD
Rasagiline—Hypertonia—Doxorubicin—liver cancer	0.00104	0.0021	CcSEcCtD
Rasagiline—Eczema—Epirubicin—liver cancer	0.00104	0.00209	CcSEcCtD
Rasagiline—Eye pain—Epirubicin—liver cancer	0.00103	0.00208	CcSEcCtD
Rasagiline—Gastrointestinal pain—Sorafenib—liver cancer	0.00101	0.00204	CcSEcCtD
Rasagiline—Renal failure acute—Epirubicin—liver cancer	0.00101	0.00204	CcSEcCtD
Rasagiline—Phlebitis—Doxorubicin—liver cancer	0.001	0.00202	CcSEcCtD
Rasagiline—Thrombophlebitis—Doxorubicin—liver cancer	0.000996	0.00201	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Epirubicin—liver cancer	0.000988	0.00199	CcSEcCtD
Rasagiline—Urticaria—Sorafenib—liver cancer	0.000984	0.00199	CcSEcCtD
Rasagiline—Abdominal pain—Sorafenib—liver cancer	0.00098	0.00198	CcSEcCtD
Rasagiline—Body temperature increased—Sorafenib—liver cancer	0.00098	0.00198	CcSEcCtD
Rasagiline—Dermatitis bullous—Epirubicin—liver cancer	0.000975	0.00197	CcSEcCtD
Rasagiline—Purpura—Epirubicin—liver cancer	0.000967	0.00195	CcSEcCtD
Rasagiline—Vascular purpura—Doxorubicin—liver cancer	0.000964	0.00194	CcSEcCtD
Rasagiline—Eczema—Doxorubicin—liver cancer	0.000959	0.00193	CcSEcCtD
Rasagiline—Eye pain—Doxorubicin—liver cancer	0.000955	0.00193	CcSEcCtD
Rasagiline—Cardiac failure—Epirubicin—liver cancer	0.000955	0.00193	CcSEcCtD
Rasagiline—Cerebrovascular accident—Epirubicin—liver cancer	0.000951	0.00192	CcSEcCtD
Rasagiline—Renal failure acute—Doxorubicin—liver cancer	0.000934	0.00188	CcSEcCtD
Rasagiline—Osteoarthritis—Epirubicin—liver cancer	0.000932	0.00188	CcSEcCtD
Rasagiline—Diplopia—Epirubicin—liver cancer	0.000932	0.00188	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000932	0.00188	CcSEcCtD
Rasagiline—Migraine—Epirubicin—liver cancer	0.000917	0.00185	CcSEcCtD
Rasagiline—Affect lability—Epirubicin—liver cancer	0.000917	0.00185	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000914	0.00184	CcSEcCtD
Rasagiline—Hypersensitivity—Sorafenib—liver cancer	0.000913	0.00184	CcSEcCtD
Rasagiline—Dermatitis bullous—Doxorubicin—liver cancer	0.000902	0.00182	CcSEcCtD
Rasagiline—Face oedema—Epirubicin—liver cancer	0.0009	0.00181	CcSEcCtD
Rasagiline—Purpura—Doxorubicin—liver cancer	0.000895	0.0018	CcSEcCtD
Rasagiline—Asthenia—Sorafenib—liver cancer	0.000889	0.00179	CcSEcCtD
Rasagiline—Cardiac failure—Doxorubicin—liver cancer	0.000883	0.00178	CcSEcCtD
Rasagiline—Mood swings—Epirubicin—liver cancer	0.000883	0.00178	CcSEcCtD
Rasagiline—Cerebrovascular accident—Doxorubicin—liver cancer	0.00088	0.00177	CcSEcCtD
Rasagiline—Pruritus—Sorafenib—liver cancer	0.000877	0.00177	CcSEcCtD
Rasagiline—Ataxia—Epirubicin—liver cancer	0.000876	0.00177	CcSEcCtD
Rasagiline—Osteoarthritis—Doxorubicin—liver cancer	0.000862	0.00174	CcSEcCtD
Rasagiline—Diplopia—Doxorubicin—liver cancer	0.000862	0.00174	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000862	0.00174	CcSEcCtD
Rasagiline—Liver function test abnormal—Epirubicin—liver cancer	0.00086	0.00173	CcSEcCtD
Rasagiline—Orthostatic hypotension—Epirubicin—liver cancer	0.000851	0.00172	CcSEcCtD
Rasagiline—Migraine—Doxorubicin—liver cancer	0.000849	0.00171	CcSEcCtD
Rasagiline—Affect lability—Doxorubicin—liver cancer	0.000849	0.00171	CcSEcCtD
Rasagiline—Diarrhoea—Sorafenib—liver cancer	0.000848	0.00171	CcSEcCtD
Rasagiline—Face oedema—Doxorubicin—liver cancer	0.000832	0.00168	CcSEcCtD
Rasagiline—Muscular weakness—Epirubicin—liver cancer	0.000822	0.00166	CcSEcCtD
Rasagiline—Dizziness—Sorafenib—liver cancer	0.000819	0.00165	CcSEcCtD
Rasagiline—Mood swings—Doxorubicin—liver cancer	0.000817	0.00165	CcSEcCtD
Rasagiline—Ataxia—Doxorubicin—liver cancer	0.000811	0.00163	CcSEcCtD
Rasagiline—Influenza—Epirubicin—liver cancer	0.000805	0.00162	CcSEcCtD
Rasagiline—Asthma—Epirubicin—liver cancer	0.000805	0.00162	CcSEcCtD
Rasagiline—Dysphagia—Epirubicin—liver cancer	0.000805	0.00162	CcSEcCtD
Rasagiline—Liver function test abnormal—Doxorubicin—liver cancer	0.000796	0.00161	CcSEcCtD
Rasagiline—Vomiting—Sorafenib—liver cancer	0.000788	0.00159	CcSEcCtD
Rasagiline—Orthostatic hypotension—Doxorubicin—liver cancer	0.000787	0.00159	CcSEcCtD
Rasagiline—Angina pectoris—Epirubicin—liver cancer	0.000784	0.00158	CcSEcCtD
Rasagiline—Rash—Sorafenib—liver cancer	0.000781	0.00158	CcSEcCtD
Rasagiline—Dermatitis—Sorafenib—liver cancer	0.000781	0.00157	CcSEcCtD
Rasagiline—Headache—Sorafenib—liver cancer	0.000776	0.00157	CcSEcCtD
Rasagiline—Muscular weakness—Doxorubicin—liver cancer	0.00076	0.00153	CcSEcCtD
Rasagiline—Dysuria—Epirubicin—liver cancer	0.000753	0.00152	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Epirubicin—liver cancer	0.000748	0.00151	CcSEcCtD
Rasagiline—Asthma—Doxorubicin—liver cancer	0.000745	0.0015	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—liver cancer	0.000745	0.0015	CcSEcCtD
Rasagiline—Influenza—Doxorubicin—liver cancer	0.000745	0.0015	CcSEcCtD
Rasagiline—Pollakiuria—Epirubicin—liver cancer	0.000744	0.0015	CcSEcCtD
Rasagiline—Nausea—Sorafenib—liver cancer	0.000736	0.00148	CcSEcCtD
Rasagiline—Photosensitivity reaction—Epirubicin—liver cancer	0.000735	0.00148	CcSEcCtD
Rasagiline—Weight decreased—Epirubicin—liver cancer	0.000729	0.00147	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—liver cancer	0.000726	0.00146	CcSEcCtD
Rasagiline—Infestation NOS—Epirubicin—liver cancer	0.000718	0.00145	CcSEcCtD
Rasagiline—Infestation—Epirubicin—liver cancer	0.000718	0.00145	CcSEcCtD
Rasagiline—Neuropathy peripheral—Epirubicin—liver cancer	0.000704	0.00142	CcSEcCtD
Rasagiline—Stomatitis—Epirubicin—liver cancer	0.0007	0.00141	CcSEcCtD
Rasagiline—Jaundice—Epirubicin—liver cancer	0.0007	0.00141	CcSEcCtD
Rasagiline—Conjunctivitis—Epirubicin—liver cancer	0.000698	0.00141	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—liver cancer	0.000697	0.00141	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000693	0.0014	CcSEcCtD
Rasagiline—Sweating—Epirubicin—liver cancer	0.000688	0.00139	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—liver cancer	0.000688	0.00139	CcSEcCtD
Rasagiline—Haematuria—Epirubicin—liver cancer	0.000685	0.00138	CcSEcCtD
Rasagiline—Photosensitivity reaction—Doxorubicin—liver cancer	0.00068	0.00137	CcSEcCtD
Rasagiline—Epistaxis—Epirubicin—liver cancer	0.000677	0.00137	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—liver cancer	0.000674	0.00136	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—liver cancer	0.000664	0.00134	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—liver cancer	0.000664	0.00134	CcSEcCtD
Rasagiline—Neuropathy peripheral—Doxorubicin—liver cancer	0.000651	0.00131	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—liver cancer	0.000648	0.00131	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—liver cancer	0.000648	0.00131	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—liver cancer	0.000648	0.00131	CcSEcCtD
Rasagiline—Rhinitis—Epirubicin—liver cancer	0.000646	0.0013	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—liver cancer	0.000646	0.0013	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—liver cancer	0.000645	0.0013	CcSEcCtD
Rasagiline—Hypoaesthesia—Epirubicin—liver cancer	0.000641	0.00129	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—liver cancer	0.000637	0.00128	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—liver cancer	0.000637	0.00128	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—liver cancer	0.000635	0.00128	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—liver cancer	0.000633	0.00128	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—liver cancer	0.000633	0.00128	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—liver cancer	0.000632	0.00127	CcSEcCtD
Rasagiline—Epistaxis—Doxorubicin—liver cancer	0.000627	0.00126	CcSEcCtD
Rasagiline—Eye disorder—Epirubicin—liver cancer	0.000602	0.00121	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—liver cancer	0.000599	0.00121	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—liver cancer	0.000598	0.00121	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—liver cancer	0.000598	0.00121	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—liver cancer	0.000596	0.0012	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—liver cancer	0.000593	0.0012	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—liver cancer	0.000589	0.00119	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—liver cancer	0.000588	0.00118	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—liver cancer	0.000586	0.00118	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—liver cancer	0.000585	0.00118	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—liver cancer	0.000585	0.00118	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—liver cancer	0.000582	0.00117	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—liver cancer	0.000581	0.00117	CcSEcCtD
Rasagiline—Chills—Epirubicin—liver cancer	0.000578	0.00117	CcSEcCtD
Rasagiline—Alopecia—Epirubicin—liver cancer	0.00057	0.00115	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—liver cancer	0.000565	0.00114	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—liver cancer	0.000561	0.00113	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—liver cancer	0.00056	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.00056	0.00111	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000558	0.00111	CbGpPWpGaD
Rasagiline—Eye disorder—Doxorubicin—liver cancer	0.000557	0.00112	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—liver cancer	0.000554	0.00112	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—liver cancer	0.000553	0.00112	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1A—liver cancer	0.00055	0.00109	CbGpPWpGaD
Rasagiline—Dysgeusia—Epirubicin—liver cancer	0.00055	0.00111	CcSEcCtD
Rasagiline—Back pain—Epirubicin—liver cancer	0.000543	0.00109	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—liver cancer	0.000541	0.00109	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—liver cancer	0.00054	0.00109	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—liver cancer	0.000539	0.00109	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—liver cancer	0.000538	0.00108	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MAPK8—liver cancer	0.000537	0.00107	CbGpPWpGaD
Rasagiline—Chills—Doxorubicin—liver cancer	0.000535	0.00108	CcSEcCtD
Rasagiline—MAOB—Metabolism—EPT1—liver cancer	0.000532	0.00106	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CG—liver cancer	0.000532	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—liver cancer	0.000531	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000529	0.00105	CbGpPWpGaD
Rasagiline—Alopecia—Doxorubicin—liver cancer	0.000527	0.00106	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—liver cancer	0.000523	0.00104	CbGpPWpGaD
Rasagiline—Mental disorder—Doxorubicin—liver cancer	0.000523	0.00105	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—liver cancer	0.000521	0.00103	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Epirubicin—liver cancer	0.000521	0.00105	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—liver cancer	0.000519	0.00103	CbGpPWpGaD
Rasagiline—Malnutrition—Doxorubicin—liver cancer	0.000519	0.00105	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—liver cancer	0.000519	0.00105	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—liver cancer	0.000517	0.00103	CbGpPWpGaD
Rasagiline—Agitation—Epirubicin—liver cancer	0.000516	0.00104	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—liver cancer	0.000512	0.00103	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000511	0.00101	CbGpPWpGaD
Rasagiline—Dysgeusia—Doxorubicin—liver cancer	0.000508	0.00103	CcSEcCtD
Rasagiline—Malaise—Epirubicin—liver cancer	0.000506	0.00102	CcSEcCtD
Rasagiline—MAOB—Metabolism—TAT—liver cancer	0.000504	0.001	CbGpPWpGaD
Rasagiline—Vertigo—Epirubicin—liver cancer	0.000504	0.00102	CcSEcCtD
Rasagiline—Syncope—Epirubicin—liver cancer	0.000503	0.00101	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000503	0.000997	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.000503	0.000997	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.000503	0.000997	CbGpPWpGaD
Rasagiline—Leukopenia—Epirubicin—liver cancer	0.000502	0.00101	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—liver cancer	0.000502	0.00101	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—BRAF—liver cancer	0.0005	0.000991	CbGpPWpGaD
Rasagiline—Muscle spasms—Doxorubicin—liver cancer	0.000499	0.00101	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—liver cancer	0.000493	0.000995	CcSEcCtD
Rasagiline—Cough—Epirubicin—liver cancer	0.00049	0.000987	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MTOR—liver cancer	0.000489	0.000971	CbGpPWpGaD
Rasagiline—Convulsion—Epirubicin—liver cancer	0.000486	0.00098	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—liver cancer	0.000484	0.000977	CcSEcCtD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000484	0.00096	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Doxorubicin—liver cancer	0.000482	0.000971	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—liver cancer	0.00048	0.000968	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—liver cancer	0.000478	0.000963	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—liver cancer	0.000478	0.000963	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—liver cancer	0.000477	0.000962	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—liver cancer	0.000476	0.00096	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000474	0.000957	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—liver cancer	0.000472	0.000952	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.00047	0.000933	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—liver cancer	0.000469	0.00093	CbGpPWpGaD
Rasagiline—Malaise—Doxorubicin—liver cancer	0.000468	0.000944	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PIK3CD—liver cancer	0.000467	0.000927	CbGpPWpGaD
Rasagiline—Dry mouth—Epirubicin—liver cancer	0.000467	0.000942	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—liver cancer	0.000466	0.000941	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—liver cancer	0.000466	0.000939	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—liver cancer	0.000465	0.000937	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—JUN—liver cancer	0.000465	0.000922	CbGpPWpGaD
Rasagiline—Confusional state—Epirubicin—liver cancer	0.000462	0.000931	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—liver cancer	0.000461	0.000915	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000459	0.00091	CbGpPWpGaD
Rasagiline—Loss of consciousness—Doxorubicin—liver cancer	0.000456	0.00092	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—liver cancer	0.000456	0.000905	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—liver cancer	0.000455	0.000903	CbGpPWpGaD
Rasagiline—Infection—Epirubicin—liver cancer	0.000455	0.000917	CcSEcCtD
Rasagiline—Cough—Doxorubicin—liver cancer	0.000453	0.000914	CcSEcCtD
Rasagiline—Shock—Epirubicin—liver cancer	0.000451	0.000909	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—CDKN1A—liver cancer	0.00045	0.000893	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CASP3—liver cancer	0.00045	0.000893	CbGpPWpGaD
Rasagiline—Convulsion—Doxorubicin—liver cancer	0.00045	0.000907	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—liver cancer	0.000449	0.000906	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—liver cancer	0.000448	0.000904	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000447	0.000887	CbGpPWpGaD
Rasagiline—Skin disorder—Epirubicin—liver cancer	0.000445	0.000897	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—liver cancer	0.000443	0.000893	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—liver cancer	0.000442	0.000891	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—liver cancer	0.000442	0.000891	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—liver cancer	0.000441	0.000876	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—liver cancer	0.000441	0.000875	CbGpPWpGaD
Rasagiline—Anxiety—Doxorubicin—liver cancer	0.000441	0.000888	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.00044	0.000872	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000439	0.000885	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—liver cancer	0.000438	0.000869	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—JUN—liver cancer	0.000437	0.000868	CbGpPWpGaD
Rasagiline—Discomfort—Doxorubicin—liver cancer	0.000437	0.000881	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—liver cancer	0.000437	0.00088	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—liver cancer	0.000434	0.000861	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000434	0.00086	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—liver cancer	0.000433	0.000859	CbGpPWpGaD
Rasagiline—Dry mouth—Doxorubicin—liver cancer	0.000432	0.000872	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—liver cancer	0.000428	0.000863	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—liver cancer	0.000427	0.000862	CcSEcCtD
Rasagiline—BCL2—Apoptosis—CTNNB1—liver cancer	0.000425	0.000843	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—liver cancer	0.000422	0.000836	CbGpPWpGaD
Rasagiline—Infection—Doxorubicin—liver cancer	0.000421	0.000849	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000417	0.000841	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—RAF1—liver cancer	0.000417	0.000828	CbGpPWpGaD
Rasagiline—Shock—Doxorubicin—liver cancer	0.000417	0.000841	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000417	0.000827	CbGpPWpGaD
Rasagiline—Nervous system disorder—Doxorubicin—liver cancer	0.000416	0.000838	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000415	0.000824	CbGpPWpGaD
Rasagiline—Insomnia—Epirubicin—liver cancer	0.000414	0.000835	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—liver cancer	0.000412	0.00083	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—liver cancer	0.000411	0.000829	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—liver cancer	0.00041	0.000826	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—liver cancer	0.000408	0.000823	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PIK3CB—liver cancer	0.000407	0.000808	CbGpPWpGaD
Rasagiline—Somnolence—Epirubicin—liver cancer	0.000407	0.000821	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000407	0.000806	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MAPK8—liver cancer	0.000405	0.000804	CbGpPWpGaD
Rasagiline—Anorexia—Doxorubicin—liver cancer	0.000404	0.000815	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—liver cancer	0.000403	0.000813	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000402	0.000798	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000401	0.000796	CbGpPWpGaD
Rasagiline—Decreased appetite—Epirubicin—liver cancer	0.000398	0.000803	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000397	0.000787	CbGpPWpGaD
Rasagiline—Hypotension—Doxorubicin—liver cancer	0.000396	0.000798	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—liver cancer	0.000395	0.000797	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.000392	0.000778	CbGpPWpGaD
Rasagiline—Constipation—Epirubicin—liver cancer	0.000392	0.00079	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—liver cancer	0.00039	0.000773	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—liver cancer	0.000387	0.000768	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000386	0.000779	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—liver cancer	0.000386	0.000766	CbGpPWpGaD
Rasagiline—Insomnia—Doxorubicin—liver cancer	0.000383	0.000773	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000382	0.000759	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—liver cancer	0.000382	0.000758	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000381	0.000755	CbGpPWpGaD
Rasagiline—Paraesthesia—Doxorubicin—liver cancer	0.000381	0.000767	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.000378	0.00075	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—liver cancer	0.000378	0.000762	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—liver cancer	0.000377	0.000761	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—liver cancer	0.000377	0.00076	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—liver cancer	0.000375	0.000743	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Epirubicin—liver cancer	0.000374	0.000755	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—NAT2—liver cancer	0.000374	0.000742	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000373	0.00074	CbGpPWpGaD
Rasagiline—Dyspepsia—Doxorubicin—liver cancer	0.000373	0.000752	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—IFNA1—liver cancer	0.000372	0.000738	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—liver cancer	0.000369	0.000732	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	0.000369	0.000732	CbGpPWpGaD
Rasagiline—Decreased appetite—Doxorubicin—liver cancer	0.000368	0.000743	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000366	0.000738	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—CCND1—liver cancer	0.000365	0.000723	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—JUN—liver cancer	0.000364	0.000722	CbGpPWpGaD
Rasagiline—Urticaria—Epirubicin—liver cancer	0.000364	0.000734	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000363	0.00072	CbGpPWpGaD
Rasagiline—Constipation—Doxorubicin—liver cancer	0.000362	0.000731	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000362	0.000719	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—liver cancer	0.000362	0.000719	CbGpPWpGaD
Rasagiline—Body temperature increased—Epirubicin—liver cancer	0.000362	0.00073	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—liver cancer	0.000362	0.00073	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—liver cancer	0.000361	0.000716	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.00036	0.000713	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—liver cancer	0.000358	0.000711	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—liver cancer	0.000353	0.000701	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—liver cancer	0.000352	0.000697	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000351	0.000697	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—liver cancer	0.000349	0.000704	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—liver cancer	0.000347	0.000699	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—MAPK8—liver cancer	0.000344	0.000683	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTP1—liver cancer	0.000344	0.000681	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000343	0.00068	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GLUL—liver cancer	0.000343	0.00068	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CPT1B—liver cancer	0.000343	0.00068	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—liver cancer	0.000337	0.00068	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—liver cancer	0.000337	0.000679	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—liver cancer	0.000335	0.000675	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—liver cancer	0.000335	0.000675	CcSEcCtD
Rasagiline—MAOB—Metabolism—NR1H4—liver cancer	0.000331	0.000656	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.00033	0.000654	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PRKCE—liver cancer	0.000329	0.000653	CbGpPWpGaD
Rasagiline—Asthenia—Epirubicin—liver cancer	0.000329	0.000663	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTA3—liver cancer	0.000325	0.000645	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—liver cancer	0.000325	0.000644	CbGpPWpGaD
Rasagiline—Pruritus—Epirubicin—liver cancer	0.000324	0.000653	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—liver cancer	0.000321	0.000636	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—VEGFA—liver cancer	0.000318	0.000631	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000317	0.000628	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—liver cancer	0.000316	0.000628	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTM1—liver cancer	0.000316	0.000626	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	0.000314	0.000622	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—liver cancer	0.000313	0.000632	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ABL1—liver cancer	0.000313	0.000621	CbGpPWpGaD
Rasagiline—Hypersensitivity—Doxorubicin—liver cancer	0.000312	0.00063	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000309	0.000613	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—liver cancer	0.000307	0.000608	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—liver cancer	0.000304	0.000613	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—liver cancer	0.000303	0.000611	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—liver cancer	0.0003	0.000605	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000299	0.000593	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTA4—liver cancer	0.000297	0.00059	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000291	0.000578	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—liver cancer	0.000291	0.000587	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000291	0.000576	CbGpPWpGaD
Rasagiline—Diarrhoea—Doxorubicin—liver cancer	0.00029	0.000585	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTA2—liver cancer	0.00029	0.000575	CbGpPWpGaD
Rasagiline—Rash—Epirubicin—liver cancer	0.000289	0.000582	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—liver cancer	0.000289	0.000573	CbGpPWpGaD
Rasagiline—Dermatitis—Epirubicin—liver cancer	0.000288	0.000582	CcSEcCtD
Rasagiline—Headache—Epirubicin—liver cancer	0.000287	0.000579	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000283	0.000562	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000283	0.000562	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—liver cancer	0.000283	0.000561	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—liver cancer	0.00028	0.000565	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTA1—liver cancer	0.000279	0.000554	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000277	0.00055	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000276	0.000548	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NAT2—liver cancer	0.000276	0.000548	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—liver cancer	0.000272	0.000549	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000271	0.000538	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.00027	0.000535	CbGpPWpGaD
Rasagiline—Vomiting—Doxorubicin—liver cancer	0.000269	0.000543	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000269	0.000534	CbGpPWpGaD
Rasagiline—Rash—Doxorubicin—liver cancer	0.000267	0.000539	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—liver cancer	0.000267	0.000538	CcSEcCtD
Rasagiline—Headache—Doxorubicin—liver cancer	0.000265	0.000535	CcSEcCtD
Rasagiline—MAOB—Metabolism—ALDOB—liver cancer	0.000265	0.000525	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ADAM17—liver cancer	0.000263	0.000522	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000261	0.000518	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CRABP1—liver cancer	0.000253	0.000501	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—liver cancer	0.000252	0.000508	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—BCL2L1—liver cancer	0.000249	0.000494	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—liver cancer	0.000248	0.000493	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PSMA4—liver cancer	0.000247	0.000491	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PSMD10—liver cancer	0.000247	0.000491	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000247	0.000491	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—liver cancer	0.000244	0.000484	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.000244	0.000483	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.00024	0.000477	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.000239	0.000475	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—liver cancer	0.000239	0.000474	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAPK14—liver cancer	0.000236	0.000468	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000236	0.000467	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—HRAS—liver cancer	0.00023	0.000456	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000224	0.000444	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HPGDS—liver cancer	0.000221	0.000438	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000217	0.00043	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA1—liver cancer	0.000217	0.00043	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000216	0.000429	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—AKT1—liver cancer	0.000203	0.000402	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.000202	0.000401	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000202	0.0004	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000202	0.0004	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.000201	0.000399	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.0002	0.000397	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000198	0.000393	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSMA4—liver cancer	0.000197	0.000391	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSMD10—liver cancer	0.000197	0.000391	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CD—liver cancer	0.000192	0.000381	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PRKCE—liver cancer	0.000192	0.00038	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GOT2—liver cancer	0.000192	0.00038	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.000185	0.000366	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ABL1—liver cancer	0.000182	0.000362	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000182	0.000361	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2E1—liver cancer	0.00018	0.000357	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000178	0.000353	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000175	0.000347	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000173	0.000343	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000172	0.000341	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAF1—liver cancer	0.000172	0.00034	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HGF—liver cancer	0.000171	0.00034	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.00017	0.000338	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—liver cancer	0.00017	0.000336	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CSF2—liver cancer	0.00017	0.000336	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYCS—liver cancer	0.000168	0.000334	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MTOR—liver cancer	0.000167	0.000332	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CB—liver cancer	0.000167	0.000332	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GOT1—liver cancer	0.000165	0.000328	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GGT1—liver cancer	0.000165	0.000328	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1B—liver cancer	0.000157	0.000312	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—JUN—liver cancer	0.00015	0.000297	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTP1—liver cancer	0.000148	0.000295	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTNNB1—liver cancer	0.000148	0.000295	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HMOX1—liver cancer	0.000146	0.000291	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1A—liver cancer	0.000145	0.000288	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BCL2L1—liver cancer	0.000145	0.000288	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAPK8—liver cancer	0.000142	0.000281	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK14—liver cancer	0.000137	0.000272	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTM1—liver cancer	0.000136	0.000271	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000131	0.000261	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UGDH—liver cancer	0.000131	0.00026	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP1A1—liver cancer	0.000129	0.000257	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EPT1—liver cancer	0.000123	0.000244	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—MTHFR—liver cancer	0.000121	0.000239	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARA—liver cancer	0.000118	0.000235	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—liver cancer	0.000117	0.000232	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TAT—liver cancer	0.000117	0.000232	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000115	0.000228	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—liver cancer	0.000112	0.000222	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—liver cancer	0.000111	0.00022	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—liver cancer	0.000102	0.000203	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—liver cancer	0.000101	0.000201	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAF1—liver cancer	9.99e-05	0.000198	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—liver cancer	9.78e-05	0.000194	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—liver cancer	9.76e-05	0.000194	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MTOR—liver cancer	9.76e-05	0.000194	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—liver cancer	9.45e-05	0.000187	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1B—liver cancer	9.15e-05	0.000182	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—liver cancer	9.04e-05	0.000179	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—liver cancer	8.96e-05	0.000178	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—liver cancer	8.91e-05	0.000177	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALB—liver cancer	8.79e-05	0.000174	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JUN—liver cancer	8.72e-05	0.000173	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—liver cancer	8.65e-05	0.000172	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.59e-05	0.00017	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—liver cancer	8.45e-05	0.000168	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—liver cancer	8.34e-05	0.000165	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK8—liver cancer	8.25e-05	0.000164	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CPT1B—liver cancer	7.93e-05	0.000157	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GLUL—liver cancer	7.93e-05	0.000157	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—liver cancer	7.76e-05	0.000154	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NR1H4—liver cancer	7.65e-05	0.000152	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—liver cancer	7.54e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA3—liver cancer	7.52e-05	0.000149	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA4—liver cancer	6.88e-05	0.000136	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.72e-05	0.000133	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA2—liver cancer	6.7e-05	0.000133	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—liver cancer	6.47e-05	0.000128	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA1—liver cancer	6.47e-05	0.000128	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAT2—liver cancer	6.39e-05	0.000127	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.15e-05	0.000122	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDOB—liver cancer	6.13e-05	0.000122	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—liver cancer	5.95e-05	0.000118	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CRABP1—liver cancer	5.85e-05	0.000116	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—liver cancer	5.5e-05	0.000109	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—liver cancer	5.27e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.27e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGDS—liver cancer	5.11e-05	0.000101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.08e-05	0.000101	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—liver cancer	4.86e-05	9.64e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—liver cancer	4.73e-05	9.39e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.63e-05	9.18e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.57e-05	9.07e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSMD10—liver cancer	4.56e-05	9.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSMA4—liver cancer	4.56e-05	9.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GOT2—liver cancer	4.43e-05	8.79e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2E1—liver cancer	4.17e-05	8.27e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.03e-05	8e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYCS—liver cancer	3.9e-05	7.73e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—liver cancer	3.87e-05	7.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GGT1—liver cancer	3.83e-05	7.59e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GOT1—liver cancer	3.83e-05	7.59e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—liver cancer	3.44e-05	6.82e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HMOX1—liver cancer	3.39e-05	6.72e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—liver cancer	3.16e-05	6.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1A1—liver cancer	2.99e-05	5.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—liver cancer	2.79e-05	5.54e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARA—liver cancer	2.74e-05	5.43e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.46e-05	4.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—liver cancer	2.35e-05	4.65e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—liver cancer	2.26e-05	4.49e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—liver cancer	2.06e-05	4.09e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALB—liver cancer	2.04e-05	4.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—liver cancer	1.8e-05	3.56e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—liver cancer	1.1e-05	2.17e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—liver cancer	8.95e-06	1.78e-05	CbGpPWpGaD
